Tonix Pharmaceuticals secures commercial payer coverage for Tonmya

Tonix Pharmaceuticals (TNXP) announced an agreement with a leading group purchasing organization that provides coverage to approximately 35M U.S. commercial lives for Tonmya, a cyclobenzaprine HCl sublingual tablet. “This agreement is an important milestone in expanding patient access to TONMYA,” said Seth Lederman, president and CEO of Tonix Pharmaceuticals. “We are encouraged by this first partnership with managed care and look forward to continuing to pursue additional coverage across commercial and government channels.” Tonix also continues to progress discussions with Medicare and Medicaid, where Tonmya is currently covered under Medicaid in 38 states for approximately 55M lives. “TONMYA is a first-in-class non-opioid analgesic indicated for the treatment of fibromyalgia in adults. TONMYA is the first new FDA-approved treatment option for fibromyalgia in over 15 years. Fibromyalgia patients have experienced dissatisfaction with available therapies, with 85% of first-line treatments failing due to efficacy and tolerability.”